Abstract
Aim: Measurable residual disease (MRD) has been recognised as an important prognostic marker in acute lymphoblastic leukaemia (ALL) alongside genetic profiling. Next generation sequencing (NGS) based clonality testing facilitates identification of the full range of clonal populations with underlying DNA sequences, thereby offering improved sensitivity and specificity for MRD monitoring. Here, we interrogate the clinical utility of NGS-based MRD assay for disease monitoring in ALL.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
